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Antitumor activity of an anti-CD98 antibody
Gregory M. Hayes1, Lawrence Chinn1, Joseph M. Cantor2, Belinda Cairns1, Zoia Levashova1, Hoang Tran1,
Timothy Velilla1, Dana Duey1, John Lippincott1, Joseph Zachwieja1, Mark H. Ginsberg2 and Edward H. van der Horst1
1 Pre-Clinical Development, Igenica Biotherapeutics, CA
2 School of Medicine, University of California—San Diego, La Jolla, CA
CD98 is expressed on several tissue types and specifically upregulated on fast-cycling cells undergoing clonal expansion.
Various solid (e.g., nonsmall cell lung carcinoma) as well as hematological malignancies (e.g., acute myeloid leukemia)
overexpress CD98. We have identified a CD98-specific mouse monoclonal antibody that exhibits potent preclinical antitumor
activity against established lymphoma tumor xenografts. Additionally, the humanized antibody designated IGN523 demonstrated
robust tumor growth inhibition in leukemic cell-line derived xenograft models and was as efficacious as standard of care
carboplatin in patient-derived nonsmall lung cancer xenografts. In vitro studies revealed that IGN523 elicited strong ADCC
activity, induced lysosomal membrane permeabilization and inhibited essential amino acid transport function, ultimately resulting
in caspase-3 and -7-mediated apoptosis of tumor cells. IGN523 is currently being evaluated in a Phase I clinical trial for acute
myeloid leukemia (NCT02040506). Furthermore, preclinical data support the therapeutic potential of IGN523 in solid tumors.
CD98 is a heterodimeric protein that comprises a heavy and
light chain. The CD98 heavy chain is a type II transmembrane
glycoprotein that forms a heterodimer via covalent linkage to
one of 6 amino acid transporters.1,2 CD98 is overexpressed on
the cell surface of almost all tumor cells, regardless of tissue
origin and increased expression of a CD98-light chain, L-type
amino acid transporter 1 (LAT-1) occurs in many types of
human cancers, including breast, colon, oral, ovarian, esopha-
geal, glioma and leukemia.3,4 Increased uptake of amino acids
supports the high growth rate of cancer cells by providing the
building blocks for protein synthesis.4–6 Moreover, the higher
expression of CD98 heavy chain and LAT-1 in metastatic vs.
primary tumors suggests that over-expression of CD98/LAT-1
may facilitate progression and metastasis of human cancers.
CD98 also regulates integrin signaling by association with
integrin b-subunits, thereby controlling cell proliferation, sur-
vival, migration, epithelial adhesion and polarity.3,7 The func-
tion of CD98 in regulating both amino acid transport and
integrin signaling can contribute to the rapid proliferation
and clonal expansion of lymphocytes and tumor cells.3
The expression pattern and pleiotropic function of CD98 heavy
and light chains suggest these proteins are promising targets for
treatment of a variety of human cancers. Although small molecule
inhibitors of LAT-1 activity have demonstrated preclinical antitu-
mor activity in a number of cancer cell types, including NSCLC,
colon cancer, oral cancer and breast cancer, development of anti-
bodies against CD98 heavy chain has received less focus.5,8–10
Murine monoclonal antibodies to CD98 inhibit lymphocyte prolif-
eration and the growth of bladder cancer, lymphoma, glioma,
prostate and colon cancer cells in preclinical models.11–13
To identify therapeutic anti-CD98 antibodies with signifi-
cant antitumor activity, we used in vivo phenotypic screening.
The advantage of phenotypic screening for antibodies against
novel targets compared with the more common target-based
screening, is 2-fold.14 First, it allows for the identification of
potent functional antibodies with antitumor properties
in vivo and second, it obviates the need for prior understand-
ing of the molecular mechanism of action (MOA). Activity
in phenotypic screening is more likely to translate into thera-
peutic efficacy than activity in target-based assays.
Here, we describe the discovery and characterization of
IGN523, a humanized monoclonal antibody targeting CD98,
which possesses multiple MOAs and elicits potent in vivo
antitumor activity in several human cancer models.
Material and Methods
General materials
Recombinant His-tagged human CD98 fusion protein was
purchased from Sinobiological (Beijing, China). Antibodies
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used in flow cytometry were from Miltenyi Biotec (Cologne,
Germany) and EMD Millipore (Billerica, MA), respectively.
For crosslinking experiments, an anti-human Fcg-specific
polyclonal goat antibody (AbXL) was obtained from Jackson
ImmunoResearch Laboratories (Westgrove, PA). Murine
IgG2a antibody (clone HB-121) served as an isotype control
(ATCC, Manassas, VA). Ramos (CRL-1596), HL-60 (CCL-
240), KG-1 (CRL-8031) and B16-F10 (CRL-6475) were
obtained from ATCC. OCI-AML-3 (ACC-582) was obtained
from DMSZ (Braunschweig, Germany). Cell lines were cul-
tured according to the suppliers’ protocols. Cetuximab (Erbi-
tux, Eli Lilly, Indianapolis, IN) and rituximab (Rituxan,
Genentech, South San Francisco, CA) were used as active
controls where appropriate. The Cooperative Human Tissue
Network (CHTN) and the National Disease Research Inter-
change provided primary tumor tissue samples, respectively.
CHTN is funded by the National Cancer Institute.
Antibody-dependent cellular cytotoxicity (ADCC) and
Complement-dependent cytotoxicity (CDC) assays
The ADCC Reporter Bioassay from Promega (Madison, WI)
was used in Ramos, KG-1, OCI-AML-3 and B16-F10 accord-
ing to the manufacturer’s protocol. Briefly, the activation of
gene transcription through the nuclear factor of activated
T-cells pathway (NFAT) in the effector cells is measured.
Engineered Jurkat cells stably expressing the FcgRIIIa recep-
tor, V158 (high affinity) variant and an NFAT response
element driving expression of firefly luciferase were used as
effector cells at a ratio of 6:1 (effector to target cell ratio,
E/T). ADCC is quantified through NFAT pathway induced
luminescence.15 Assay equivalency was demonstrated using
purified human peripheral NK cells in Ramos and KG-1 cells
(Supporting Information Methods).
For CDC assays, normal human serum (10% final concen-
tration) was added to initiate the CDC cascade. Nonlinear
curve-fit (4-parameter dose-response curve fit with variable
slope) was applied and data were analyzed and graphed by
GraphPadPrism vers. 5.0f (GraphPad Software, La Jolla, CA).
Amino acid transport assay
Amino acid transport activity was tested following a modified
protocol.16 3H-labeled Phe (126 Ci/mM) was purchased from
Perkin Elmer (Santa Clara, CA). 2-aminobicyclo[2.2.1]hep-
tane-2-carboxylic acid (BCH) was obtained from Sigma-
Aldrich (St. Louis, MO). Briefly, 2 3 105 cells were incubated
with IGN523 and AbXL for 30 min prior to the addition of
3H-Phe for 2 min. Parallel cultures were treated with 10 mM
BCH to serve as a positive control. Cells were washed, lysed
and cell lysates mixed with scintillation fluid. Radioactivity
was quantified in a Perkin Elmer 1450 MicroBeta Trilux
(Santa Clara, CA).
Viability and apoptosis assays
Viability and caspase-3 and caspase-7-mediated apoptosis
were quantified using the ApoTox-Glo kit provided by Prom-
ega (Madison, WI) according to the manufacturer’s protocol.
Cells were plated at 2 3 104 cells/well onto a 96-well plate in
complete media and incubated for 24 hr. For IGN523 cross-
linking studies, cells were preincubated with 2 lg/ml IGN523
in the presence or absence of 10 lg/ml AbXL. Cells were
then incubated for 48 hr and viability and caspase-3 and
caspase-7-mediated apoptosis measured.
Lysosome volume and permeability assays
LysoTracker Deep Red and acridine orange (AO) were pur-
chased from Molecular Probes/Life Technologies (Grand
Island, NY). In both assays, following lysosome labeling,
Ramos cells were treated with 10 lg/mL IGN523 in the pres-
ence or absence of 50 lg/mL crosslinking antibody for 30 min
at 37 C. Assessment of lysosomal volume and permeability
was performed as described previously, with 3 3 106 cells
labeled either with 50 nM LysoTracker Deep Red for 1 hr or
with 5 lM acridine orange (AO) for 15 min at 37 C.17 AO is
a metachromatic fluorochrome that emits red fluorescence
when highly concentrated in acidic lysosomes and emits green
fluorescence in the more pH neutral cytosol. Leakage of lyso-
somal contents into the cytosol can be detected as an increase
in green fluorescence by flow cytometry.
Flow cytometry
Flow cytometric data were acquired using a MACSQuant
Analyzer 10 cytometer (Miltenyi Biotec, Cologne, Germany)
operated by MACSQuantify software and at least 30,000 viable
events were collected per sample. Data was analyzed using
FlowJo software (Version 10.0.7, Tree Star, Ashland, OR).
Immunofluorescence
Ramos cells were incubated at 4 C for 30 min with 2 lg/mL
Alexa488-labeled IGN523 in the presence or absence of
10 lg/mL crosslinking antibody and Hoechst (Life Technolo-
gies). Cells were subsequently incubated at 37 C for the
indicated time points (0–90 min) before being fixed with an
What’s new?
The CD98 protein is overexpressed in a wide variety of cancers, and its expression levels show positive association with
tumor progression and metastasis. Both the heavy and the light chains of CD98 are of therapeutic interest. The present study
reports broad and potent anti-tumor activity of the anti-CD98 humanized monoclonal antibody IGN523 in leukemic cell-line-
derived xenograft models and patient-derived non-small cell lung cancer xenografts. IGN523 exhibited multiple mechanisms of
action, and in vitro demonstrated antibody-dependent cellular cytotoxicity, blocked amino acid transport, and led to tumor cell
apoptosis mediated via caspase-3 and caspase-7 pathways.
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equal volume of ice cold 10% phosphate-buffered formalin.
Fixed cells were cytospun, stained with 0.2 lg/mL anti-
human LAMP1 (BD Pharmingen, San Jose, CA) and
mounted with ProLong Gold reagent (Life Technologies).
Images were taken using an IX51 microscope (Olympus,
Center Valley, PA) operated by MetaMorph imaging software
(Molecular Devices, Sunnyvale, CA).
Xenograft transplantation experiments
Patient-derived tumor tissue was passaged in vivo as
described previously.18 IGN-LNG-12 and -54 are proprietary
patient-derived lung tumor xenograft lines that were estab-
lished at Igenica Biotherapeutics. IGN-LNG-12 is a metastatic
poorly differentiated (Grade 3) NSCLC. IGN-LNG-54 is a
moderately differentiated (Grade 2) NSCLC. Immunocom-
promised female NOD/SCID mice were used for the estab-
lishment of IGN-LNG-12, IGN-LNG-54 and KG-1 tumor
xenografts, and female CB17-SCID (Swiss CD-1) mice were
used for the Ramos, HL-60 and OCI-AML-3 tumor models
(Charles River, Wilmington, MA). Mice were subcutaneously
injected on the right flank with 1 3 106 (IGN-LNG-12 and
IGN-LNG-54) or at least 1 3 107 viable cells (Ramos, HL-60,
OCI-AML-3, KG-1). When the tumor reached a size between
65 and 300 mm3, mice were randomized to treatment. Anti-
bodies were administered weekly, or as indicated, and tumors
measured twice weekly. Tumor volume was calculated using
the modified ellipsoid formula p/6(Length 3 Width2). All
experiments were performed on groups of at least eight ani-
mals per group. Animal experiments were performed in
accordance with protocols approved by the Igenica Biothera-
peutics Institutional Review Board—Animal Care and Use
Committee.
Statistical analysis
Data are either expressed as the mean6 standard error of the
mean in vivo, or 6the standard deviation, in vitro. Group
means were compared using Student’s 2-tailed, unpaired
t test. Probability (p) values of <0.05 were interpreted as sig-
nificantly different and not adjusted for multiple compari-
sons. All statistical analyses were performed using Microsoft
EXCEL (Microsoft, Redmond, WA) and GraphPad Prism
v.5.0f (GraphPad Software).
Additional and more detailed experimental procedures are
provided in Supporting Information Methods.
Results
Phenotypic in vivo screening identifies anti-CD98 antibody
that strongly inhibits tumor growth
Expression analysis of CD98 in primary AML cells and
NSCLC samples, revealed that it was overexpressed in >90%
of AML patients and approximately 55% of patients with the
squamous cell carcinoma subtype of NSCLC (Supporting
Information Figs. S1a and S1b). Consequently, we generated
human CD98-specific murine monoclonal antibodies (mAbs),
using Igenica’s cell-based in vivo immunization approach
followed by standard hybridoma technology.19 After isotype
analysis, verification of antigen specificity and epitope bin-
ning, 19 mAbs were evaluated for antitumor activity by
assessing their impact on the growth of established hetero-
topic human tumors in immunodeficient mice.19 First, the
mAbs were tested in the CD98-positive Ramos Burkitt’s lym-
phoma model (Fig. 1a; Supporting Information Fig. S1c). In
3 iterations of in vivo screening, antibody 18-2A consistently
demonstrated potent antitumor activity that was higher than
the standard of care, rituximab. 18-2A was then evaluated in
the CD98-positive Dau Burkitt’s lymphoma model where it
showed tumor growth inhibition (TGI) of 48% (p< 0.01;
Supporting Information Fig. S1d). Based on its robust antitu-
mor activity in vivo, 18-2A was selected for humanization.
Humanized anti-CD98 antibody IGN523 inhibits tumor
growth of various cancers
To verify antibody-antigen binding affinities and biological
activity were retained after the humanization process, the
binding characteristics of both 18-2A and IGN523, the
humanized version of 18-2A, were assessed by surface plas-
mon resonance and biological activity tested in vivo. The kon,
koff and KD values of 18-2A and IGN523 were nearly identi-
cal, indicating that the binding affinity toward human CD98
had been retained (Fig. 1b).
Tumor growth inhibitory characteristics were compared
between 18-2A and IGN523 by treating established Ramos
and Dau xenografts (Figs. 1c and 1d). The TGI of 18-2A and
IGN523 were very similar in Ramos (92% vs.98%, respec-
tively) and slightly higher for IGN523 in DAU (76% vs.43%),
suggesting that the antitumor properties of 18-2A were also
retained.
Because CD98 is highly expressed across many malignan-
cies, we evaluated IGN523 in a range of established CD98-
positive xenograft cancer models. IGN523 was tested in the
AML models HL-60, OCI-AML-3 and KG-1, and in 2
patient-derived NSCLC xenograft models, IGN-LNG-12 and
IGN-LNG-54 (Fig. 2). IGN523 was also compared with the
standard of care drug carboplatin in the NSCLC xenograft
models (Figs. 2d and 2e). IGN523 significantly reduced tumor
growth compared with isotype control in all 5 xenograft
models: HL-60 (94%, p< 0.001), OCI-AML-3 (74%,
p< 0.001), KG-1 (53%, p< 0.05), IGN-LNG-12 (44%,
p< 0.001) and IGN-LNG-54 (56%, p< 0.001). Notably,
although carboplatin at its maximal tolerated dose produced
a significant TGI in IGN-LNG-12 (44%, p< 0.001) and IGN-
LNG-54 (31%, p< 0.05), it also resulted in toxicity as evi-
denced by marked body weight loss (17.66 1.3 g final weight
in IGN-LNG-12; 22.26 2.4 g final weight in IGN-LNG-54;
Supporting Information Fig. S2). In contrast, IGN523 treat-
ment exerted comparable or higher antitumor effect com-
pared with carboplatin (56% vs.31% in IGN-LNG-54,
p5 0.04), without inducing body weight loss (20.16 1.8 g
final weight in IGN-LNG-12; 25.66 2 g final weight in
IGN-LNG-54). These data demonstrate that IGN523
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treatment is as effective as carboplatin without inducing body
weight loss in NOD/SCID mice.
In addition to measuring TGI, CD98 expression was
examined in the patient-derived xenografts by staining tumor
tissue sections with a polyclonal rabbit anti-CD98 antibody
post-treatment (Fig. 2f). CD98 expression was completely
abrogated in the IGN523 treatment group, while CD98 levels
were unchanged in the control and carboplatin treatment
groups. This suggests that IGN523-mediated down regulation
of CD98 led to elimination of CD981-tumor cells.
Figure 1. Antitumor activity of anti-CD98 antibodies in Burkitt’s lymphoma model ramos, biophysical properties of 18-2A and IGN523 and
comparison of their antitumor efficacy in ramos and dau Burkitt’s lymphoma xenografts. (a) of note, in studies 1 and 2, rituximab was
used as a positive control and elicited a TGI of 88% (p<0.001) and 68% (p<0.001), respectively. (b) biacore analysis of 18-2A (murine
IgG2a) and IGN523 (human IgG1) on recombinant human CD98 protein. (c) ramos or (d) dau growth curves in mice receiving 18-2A (15 mg/kg),
IGN523 (15 mg/kg) or control antibody (control IgG; 15 mg/kg) once weekly intraperitoneally (i.p.) (n58); (c) ***p<0.001 versus control,
(d) *p<0.05; **p<0.01 relative to control. Treatment started on day of randomization. Starting tumor volumes were 2486112 and
111638 mm3 for ramos and dau, respectively. Please note no statistical difference between 18-2A and IGN523 treatment groups in ramos.
Arrow5 administration of antibody; N.S.5 statistically not significant; n.a.5 not applicable.
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Figure 2. Tumor growth inhibition of IGN523 in different tumor models. (a) HL-60, (b) OCI-AML-3, (c) KG-1, (d) IGN-LNG-12 and (e) IGN-LNG-54
growth curves in either NOD/SCID- (c–e) or CB.17-SCID-mice (a and b) receiving IGN523 (15 mg/kg) or control IgG (15 mg/kg). Carboplatin
was administered in IGN-LNG-12 and IGN-LNG-54 at 10 mg/kg i.p. (n58). (f) anti-CD98 staining of representative IGN-LNG-54 tumors
post-treatment. *p<0.05; ***p<0.001 relative to control. Starting tumor volumes were 134632 mm3 (HL-60); 174634 mm3 (OCI-AML-3);
92611 mm3 (KG-1); 126623 mm3 (IGN-LNG-12) and 136638 mm3 (IGN-LNG-54). Please note a statistical difference between IGN523 and
carboplatin treatment groups in IGN-LNG-54 (p<0.04). Arrow5 administration of antibody. Scale bar520 lm.
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In summary, the humanized anti-CD98 antibody IGN523
maintained both the binding affinity and biological activity of
its parental antibody. IGN523 inhibited tumor growth in
AML and primary NSCLC xenograft models.
IGN523 elicits strong Antibody-dependent cellular
cytotoxicity, but not Complement-dependent cytotoxicity
ADCC and CDC are clinically relevant MOAs for therapeu-
tic antibodies, e.g., rituximab (anti-CD20).20 Consequently,
ADCC and CDC induction by IGN523 was evaluated
(Fig. 3). Ramos, KG-1 and OCI-AML-3 cells were used as
target cells, because they were sensitive to IGN523 treat-
ment in vivo. Rituximab and cetuximab (anti-EGFR) served
as control biologics in these evaluations. The EC50 data
demonstrated that IGN523 elicited strong ADCC activity at
18.6 ng/mL, 73.8 ng/mL and 83.3 ng/mL in Ramos, KG-1
or OCI-AML-3 cells, respectively (Figs. 3a–3c) and a signifi-
cantly greater ADCC activity in CD981- and CD201-Ramos
cells than rituximab. IGN523 did not produce CDC activity
in KG-1 cells and elicited only marginal CDC activity at
12 ng/mL in Ramos cells (Figs. 3d and 3e). As a negative
control we used the mouse melanoma cell line B16-F10 and
did not observe IGN523-induced ADCC activity, since
IGN523 specifically binds to human CD98 (Supporting
Information Fig. S4a). Therefore, ADCC is likely a contrib-
uting mechanism for antitumor activity of IGN523, while
CDC appears less important.
IGN523 elicits Caspase-dependent apoptosis, increases
lysosomal membrane permeability and decreases amino
acid transport
Another mechanism by which antibodies may exert antitu-
mor activity is receptor crosslinking on the cell surface.21 For
example, anti-CD20 antibody rituximab, initiates the mito-
chondrial apoptosis pathway, which does not necessarily
require active caspases.22 Antibody crosslinking by immune
cells expressing Fcg-receptors such as leukocytes can be ther-
apeutically beneficial by triggering pro-apoptotic stimuli in
cancer cells.21 This effect can be mimicked in vitro by using
an anti-Fc antibody, such as a polyclonal goat anti-human
IgG, AbXL.
To investigate the potential relationship between anti-
IGN523 crosslinking and tumor cell viability, Ramos, OCI-
AML-3 and KG-1 cells were treated with IGN523 in the
presence or absence of AbXL and assessed for survival
(Figs. 4a–4c). Measuring the protease activity restricted to
intact viable cells revealed that IGN523 treatment substan-
tially decreased cell viability in the presence of AbXL
(Ramos: 70% reduction, p< 0.001; OCI-AML-3: 76% reduc-
tion, p< 0.001; KG-1: 80% reduction, p< 0.001), but not
when used alone. A concomitant increase in caspase-3 and
caspase-7 activity indicated that the IGN523-induced cell
death was caspase-mediated (Ramos: 3.3-fold, p< 0.001;
OCI-AML-3: 7.5-fold, p< 0.001 and KG-1: 6.6-fold,
p< 0.001; Figs. 4d–4f).
Figure 3. IGN523 demonstrates strong ADCC-, but not CDC-activity. Antibody-induced luciferase activity in the effector cell is quantified
with luminescence readout and is a surrogate for effector cell-mediated cell lysis. Target cells (a and d) ramos, (b and e) KG-1 and (c)
OCI-AML-3 were used in (a–c) ADCC or (d and e) CDC assays. Please note that IGN523 elicits greater ADCC activity than rituximab in ramos
cells. Cetuximab (anti-EGFR) was used as negative control antibody (control IgG). Ramos, KG-1 and OCI-AML-3 cell lines both endogenously
express CD98 on the cell surface.
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CD98 heavy chain serves as a dimerization partner for any
of 6 light chain amino acid transporters, whose functional
activity depends on the presence of the heavy chain.23 Since
impairment of amino acid exchange can impair cancer cell
growth, the impact of IGN523 upon cellular import of essen-
tial amino acids was investigated in Ramos, OCI-AML-3 and
KG-1 cells (Figs. 4g–4i). The cells were treated with IGN523
plus AbXL prior to incubation with 3H-phenylalanine. In
parallel, cells were treated with 10 mM 2-aminobicyclo[2.2.1]-
heptane-2-carboxylic acid (BCH), a nonmetabolizable leucine
analogue and inhibitor of the large neutral amino acid trans-
porters LAT-1 and LAT-2,24 as a control. Crosslinking of
CD98 resulted in a significant reduction of labeled phenylala-
nine by 20–44% (Ramos), 45–70% (OCI-AML-3) and 30–34%
(KG-1), respectively, indicating that IGN523-crosslinking
reduced the transport of this essential amino acid. As a speci-
ficity control we again used the mouse melanoma cell line
B16-F10 and did not observe IGN523-mediated decrease in
Figure 4. IGN523 decreases viability, amino acid transport and increases caspase-3 and caspase-7 activity. Cells were incubated with
IGN523 in the presence or absence of AbXL. (a–c) cell viability was assessed by measurement of live-cell protease activity that is restricted
to intact viable cells (fluorescence). (d–f) Caspase-3 and caspase-7 activity was measured by increase in aminoluciferin-induced lumines-
cence through DEVD-aminoluciferin substrate cleavage. (g–i) crosslinked IGN523 reduced 3Phe-uptake. BCH was used at 10 mM. The ratio
of IGN523:AbXL was 1:5. The amount of 3Phe-uptake in ramos cells under each treatment determined as counts per minute (cpm) is
graphed. *p<0.05; ***p<0.001 relative to IGN523 (a and b) or control (c), respectively.
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cell viability, increase in caspase activity or decrease in amino
acid transport, respectively (Figs. S4b–S4d).
Enhanced ADCC activity, as well as increased lysosomal
membrane permeabilization (LMP), has been demonstrated
with crosslinked CD20.25 To assess whether similar effects are
seen with IGN523 plus crosslinker, we investigated if the
CD98-IGN523 complex was internalized to lysosomes and
whether this led to increased lysosomal permeability (Fig. 5).
Immunofluorescence studies of IGN523-treated Ramos cells in
the presence or absence of AbXL showed that the CD98-
IGN523 complex localized to lysosome-associated membrane
protein LAMP-1 structures and that the rate of internalization
Figure 5. IGN523-CD98 complex colocalizes with LAMP-1. IGN523 induces lysosomal permeability. (a) ramos cells were incubated at 4 C
for 30 min with 2 lg/mL Alexa488-labeled anti-human CD98 antibody (green), 10 lg/mL anti-human crosslinker (AbXL) and hoechst (blue).
Cells were subsequently incubated at 37 C for the indicated time points (0 or 90 min). LAMP1 was stained with anti-LAMP1-AF647 anti-
body (red). Note that CD98 and LAMP-1 colocalize (yellow). Top row: 0 min; bottom row: 90 min; scale bar510 lm. (b) lysosomal volume
and (c) lysosomal permeability was assessed in IGN523-crosslinked ramos cells at 4 and 12 hr, respectively. The ratio of IGN523 (10 lg/mL):AbXL
(50lg/mL) was 1:5. Cetuximab was used as control antibody (control IgG). ***p<0.001 relative to IGN523.
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was increased by crosslinking. Moreover, in the presence of
IGN523, CD98 seemed to be capped at the cell surface. This is
reminiscent of the CD20 distribution with rituximab treatment
that augments NK-cell-mediated ADCC26 (Fig. 5a).
We next determined whether lysosomal integrity was
impaired after internalization of the CD98-antibody complex.
Following IGN523 incubation and addition of AbXL, Ramos
cells were harvested and assessed for changes in lysosomal vol-
ume and permeability via flow cytometry (Figs. 5b and 5c).
Treatment with IGN523 and AbXL decreased the LysoTracker-
positive population by 60 and 77% at 12 and 24 hr, respec-
tively, suggesting an induction of lysosomal collapse (Fig. 5b).
LMP was assessed by measuring the increase in green fluores-
cence that occurs when AO-labeled lysosomes leak into the
cytosol17 (Fig. 5c). IGN523 increased AO green fluorescence
within 4 hr after treatment, indicating LMP. This was followed
by a decrease in green fluorescence at 12 hr. Taken together,
these data suggest the CD98-IGN523 complex is efficiently
internalized and shuttled to lysosomes. Moreover, IGN523 in
the presence of AbXL decreases lysosomal integrity and reduces
amino acid transport resulting in cell death.
Discussion
The presence of CD98 on cancer cells is well established: it
is expressed on a wide variety of solid and hematological
malignancies, and its overexpression correlates with both
poor prognosis and cellular transformation (reviewed in Refs.
3, 27). This study describes the antitumor activity of IGN523,
a humanized antibody against CD98. Phenotypic screening in
vivo enabled identification of an antibody with therapeutic
potential based on tumor growth inhibition, without detailed
a priori knowledge of its mechanism of action. A recent anal-
ysis noted that phenotypic drug discovery strategies were
more successful for first-in-class medicines, whereas target-
based molecular strategies were more successful for follow-on
drugs.14 Phenotypic screening was successful for IGN523, the
first anti-CD98 antibody to enter into clinical trial for AML
(NCT02040506).
Subsequent studies investigated the mechanisms of IG523
action. Important mechanisms responsible for the therapeutic
benefit of monoclonal antibodies in oncology include strong
ADCC activity and signal perturbation of cancer-relevant
pathways, although the role of CDC remains unclear.20,28
Because drug resistance mechanisms in cancer treatment lead
to poor patient outcomes, targeting several orthogonal path-
ways with different drugs or using a drug with multiple
mechanisms of action may delay or overcome drug resist-
ance.29 Therapeutic anti-CD20 antibodies, such as rituximab
and obinutuzumab, elicit ADCC. In addition to ADCC
induction, rituximab-mediated capping of CD20 has been
Figure 6. Mechanisms of action for IGN523. IGN523 encompasses multiple, diverse mechanisms of action. In vitro analysis of IGN523 upon
multiple tumor cells demonstrates a potent ADCC ability for this antibody. Crosslinking of IGN523 upon tumor cells significantly reduces
both the import of essential amino acids and increases lysosomal membrane permeability. Together, these MOAs resulted in caspase-3
and caspase-7 activation and cell death.
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proposed as an additional MOA, enhancing NK-mediated
cytotoxicity.26 Obinutuzumab not only possesses ADCC
activity, but also exhibits multiple MOAs in vitro, including
enhanced noncaspase-dependent induction of direct cell
death.25
Similarly, IGN523 possesses multiple mechanisms of action,
as shown here in several cell lines in vitro (Fig. 6). First, the
ADCC activity of IGN523 against Ramos, OCI-AML-3 and
KG-1 cells is robust. The data suggest that IGN523 may also
concentrate CD98 on the target cell surface, possibly inducing
a more potent ADCC activity in vivo through enhanced
NK-recruitment. Second, in these cell lines, IGN523 elicits
capase-3 and caspase-7 mediated apoptosis in the presence of
crosslinking antibody. Third, IGN523 inhibits the uptake of
the essential amino acid phenylalanine in vitro. Lastly,
CD98-IGN523 complex colocalized with LAMP-1 and led to
increased lysosomal permeability. As with anti-CD20 antibod-
ies, crosslinking antibody in vitro that simulates immune cells
expressing Fcg-receptors in vivo, enables additional cytotoxic
actions for IGN523, but with different involvement of caspases
compared with the anti-CD20 antibodies.
Targeting cancer metabolism has emerged as a promising
therapeutic approach, due to the increased metabolic demands
of cancer cells.6 Recent studies have shown that L-asparaginase
depletion of glutamine profoundly inhibits protein synthesis
and produces a strong apoptotic response in primary AML
cells.30 Importantly, CD98 is the main heterodimerization
partner for 6 amino acid transporters, which are dependent on
the CD98 heavy chain for their localization and proper func-
tion.23 Among those 6 transporters, the bi-directional trans-
porters LAT-1 and LAT-2 export nonessential glutamine to
enable the uptake of essential amino acids, which in turn acti-
vate the mammalian target of the rapamycin pathway promot-
ing cell growth and survival.31 Although biologically active
small molecules against CD98-associated light chains have
been identified, anti-CD98 antibodies provide another
approach to modifying amino acid transport.5,11–13
Our data demonstrate for the first time that CD98 is over-
expressed in CD341-primary AML cells and in the squamous
cell carcinoma subtype of NSCLC (Supporting Information
Figs. S1a and S1b). The overexpression on primary AML cells
is an important finding, since monoclonal antibody therapies,
which have been successful treatments for other hematologi-
cal malignancies such as CLL,32 have heretofore not been
successful for AML.
We have shown that IGN523 has potent antitumor activ-
ity across a variety of malignancies in vivo. The range of anti-
tumor mechanisms exhibited by IGN523 may reduce the
emergence of treatment-resistant cancer clones and improve
patient outcomes. The therapeutic potential of IGN523 is
currently being evaluated in clinical trials with AML patients
(NCT02040506).
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